A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a safe dose of LY2835219 to be given to
participants with advanced cancer and to determine any side effects that may be associated
with LY2835219 in this population. Efficacy measures will be used to assess the activity of
LY2835219 in this population.